Insmed Incorporated (INSM) - Stock Analysis
Last updated: Jun 7, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Fresh positive Phase 3 ENCORE topline (3/23) and strong 2026 revenue guidance (BRINSUPRI ≥$1B, ARIKAYCE $450–470M) have driven ~9.8% 21-day ROC and price ~13% above the 21-day SMA. With Phase 2b CEDAR topline due in Q2 2026, the stock is a high-risk but well-defined event-driven long for the coming days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Liquidity Strength • Cash Burn • Rich Valuation INSM has strong liquidity and very high gross margins, but persistent operating losses, heavy cash burn, and an expensive valuation keep the risk/reward profile weak.
Price Behavior
Key Price Behavior Insights: • Support break • Seller control • Oversold bounce Support Level: $103–$104 Resistance Level: $103–$105, then $106–$109; stronger ceiling at $117.99 INSM weakened over the last month as the drop to $94.22 broke the $103–$104 support zone, leaving sellers in control unless it quickly reclaims $103–$105.
Sentiment & News
Key News Insights: • Revenue surge • BRINSUPRI defense • Investor outreach Insmed's Q1 beat with 230% revenue growth was overshadowed by a sales miss and 23% stock drop, while frequent conference appearances and hiring signal management's push to reassure investors on BRINSUPRI and pipeline progress.
AI Summary
INSM has shifted from a binary biotech to a commercialization story with real high-margin revenue from BRINSUPRI and ARIKAYCE, but at ~57x sales the stock now depends on flawless launch/label-expansion execution to justify the valuation, making any slowdown in uptake or setback in ARIKAYCE/TPIP a likely de-rating trigger.
Description
Insmed is a biopharmaceutical company that develops and commercializes therapies for patients with serious and rare diseases, and it markets ARIKAYCE for adult Mycobacterium avium complex lung disease as part of a combination antibacterial regimen. The company’s pipeline includes Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor in development for bronchiectasis and other neutrophil-mediated conditions, and an inhaled treprostinil palmitil prodrug being studied for pulmonary arterial hypertension and other rare pulmonary disorders.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Apr 1 | Apr 8 | INSM | Insmed Incorporated | Fresh positive Phase 3 ENCORE topline (3/23) and strong 2026 revenue guidance (BRINSUPRI ≥$1B, ARIKAYCE $450–470M) have driven ~9.8% 21-day ROC and price ~13% above the 21-day SMA. With Phase 2b CEDAR topline due in Q2 2026, the stock is a high-risk but well-defined event-driven long for the coming days. | Closed | -2.8% |
| Nov 24 | Dec 1 | INSM | Insmed Incorporated | Insmed (INSM) is supported by FDA approvals, strong Q3 revenue growth (+22% ARIKAYCE®), bullish technical momentum (+24.5% over 21 days), and raised guidance reflecting commercial traction. Despite continuing losses and high valuation, ongoing pipeline catalysts and significant liquidity underpin a moderate short-term upside case. | Closed | +2.2% |